<?xml version="1.0" encoding="UTF-8"?><OAI-PMH
	xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2019-03-02T19:46:26Z</responseDate><request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:3512577" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request><GetRecord><record><header><identifier>oai:pubmedcentral.nih.gov:3512577</identifier><datestamp>2012-12-03</datestamp><setSpec>wtpa</setSpec><setSpec>pmc-open</setSpec><setSpec>manuscript</setSpec></header><metadata><article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.0/ https://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-journal-id">101186374</journal-id>
      <journal-id journal-id-type="pubmed-jr-id">31761</journal-id>
      <journal-id journal-id-type="nlm-ta">Nat Struct Mol Biol</journal-id>
      <journal-id journal-id-type="iso-abbrev">Nat. Struct. Mol. Biol.</journal-id>
      <journal-title-group>
        <journal-title>Nature structural &amp; molecular biology</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1545-9993</issn>
      <issn pub-type="epub">1545-9985</issn>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC3512577</article-id>
      <article-id pub-id-type="pmcid">PMC3512577</article-id>
      <article-id pub-id-type="pmc-uid">3512577</article-id>
      <article-id pub-id-type="pmid">21317894</article-id>
      <article-id pub-id-type="pmid">21317894</article-id>
      <article-id pub-id-type="doi">10.1038/nsmb.2018</article-id>
      <article-id pub-id-type="manuscript">ems34061</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Structural basis for engagement by complement factor H of C3b on a self surface</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Morgan</surname>
            <given-names>Hugh P.</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
          <xref ref-type="author-notes" rid="FN2">6</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Schmidt</surname>
            <given-names>Christoph Q.</given-names>
          </name>
          <xref ref-type="aff" rid="A2">2</xref>
          <xref ref-type="author-notes" rid="FN2">6</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Guariento</surname>
            <given-names>Mara</given-names>
          </name>
          <xref ref-type="aff" rid="A2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Blaum</surname>
            <given-names>BÃ¤rbel S.</given-names>
          </name>
          <xref ref-type="aff" rid="A2">2</xref>
          <xref ref-type="author-notes" rid="FN1">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gillespie</surname>
            <given-names>Dominic</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Herbert</surname>
            <given-names>Andrew P.</given-names>
          </name>
          <xref ref-type="aff" rid="A2">2</xref>
          <xref ref-type="author-notes" rid="FN1">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kavanagh</surname>
            <given-names>David</given-names>
          </name>
          <xref ref-type="aff" rid="A3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mertens</surname>
            <given-names>Haydyn D. T.</given-names>
          </name>
          <xref ref-type="aff" rid="A4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Svergun</surname>
            <given-names>Dmitri I.</given-names>
          </name>
          <xref ref-type="aff" rid="A4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Johansson</surname>
            <given-names>Conny M.</given-names>
          </name>
          <xref ref-type="aff" rid="A2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>UhrÃ­n</surname>
            <given-names>DuÅ¡an</given-names>
          </name>
          <xref ref-type="aff" rid="A2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Barlow</surname>
            <given-names>Paul N.</given-names>
          </name>
          <xref ref-type="aff" rid="A2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hannan</surname>
            <given-names>Jonathan P.</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
      </contrib-group>
      <aff id="A1"><label>1</label>Institute of Structural and Molecular Biology, School of Biological Sciences, Kingâs Buildings, Mayfield Road, University of Edinburgh, Edinburgh, EH9 3JR, UK
</aff>
      <aff id="A2"><label>2</label>Edinburgh Biomolecular NMR Unit, EaStCHEM, School of Chemistry, University of Edinburgh, Edinburgh, EH9 3JJ, UK
</aff>
      <aff id="A3"><label>3</label>The Institute of Human Genetics, University of Newcastle upon Tyne, NE1 3BZ, UK
</aff>
      <aff id="A4"><label>4</label>European Molecular Biology Laboratory, Hamburg Outstation, NotkestraÃe 85, D-22603 Hamburg, Germany
</aff>
      <author-notes>
        <corresp id="CR1">Correspondence should be addressed to P.N.B (<email>Paul.Barlow@ed.ac.uk</email>) or J.P.H. (<email>Jonathan.Hannan@ed.ac.uk</email>).</corresp>
        <fn fn-type="present-address" id="FN1">
          <label>5</label>
          <p id="P1">Present address: Interfaculty Institute for Biochemistry, University of TÃ¼bingen, D-72076 TÃ¼bingen, Germany (B.S.B); The Physiological Laboratory, School of Biomedical Sciences, Crown Street, University of Liverpool, Liverpool, L69 3BX, UK (A.P.H).</p>
        </fn>
        <fn fn-type="equal" id="FN2">
          <label>6</label>
          <p id="P2">Denotes each author contributed equally to this study</p>
        </fn>
        <fn id="FN5">
          <p id="P3">
            <bold>AUTHOR CONTRIBUTIONS</bold>
          </p>
          <p id="P4">M.G, C.Q.S, D.K and A.P.H engineered and produced FH proteins; J.P.H and D.G engineered and produced C3d proteins; C.J.M. generated dp8 fragments. J.P.H and D.G crystallized the C3d:FH complex; H.P.M and J.P.H collected crystallographic data; H.P.M determined and refined the structure; B.S.B produced <sup>15</sup>N-labeled FH and carried out NMR studies of the FH:C3d, and FH:dp8 interactions; B.S.B and A.P.H carried out the hemolysis assay; J.P.H carried out the C3d:dp8 competition ELISA; C.Q.S and M.G carried out the SPR measurements; H.D.T.M and D.I.S carried out the SAXS analysis; D.U, J.P.H and P.N.B conceived and supervised the project. H.P.M, C.Q.S, M.G, B.B, D.U, J.P.H and P.NB wrote the manuscript</p>
        </fn>
      </author-notes>
      <pub-date pub-type="nihms-submitted">
        <day>25</day>
        <month>1</month>
        <year>2011</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>13</day>
        <month>2</month>
        <year>2011</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <month>4</month>
        <year>2011</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>03</day>
        <month>12</month>
        <year>2012</year>
      </pub-date>
      <volume>18</volume>
      <issue>4</issue>
      <fpage>463</fpage>
      <lpage>470</lpage>
      <permissions>
        <license>
          <license-p>Users may view, print, copy, download and text and data- mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:
<uri xlink:type="simple" xlink:href="http://www.nature.com/authors/editorial_policies/license.html#terms">http://www.nature.com/authors/editorial_policies/license.html#terms</uri></license-p>
        </license>
      </permissions>
      <abstract>
        <p id="P5">Complement factor H (FH) attenuates C3b molecules tethered via their thioester domains to self-surfaces and thereby protects host tissues. FH is a cofactor for initial C3b proteolysis that ultimately yields a surface-attached fragment (C3d), corresponding to the thioester domain. We used NMR and X-ray crystallography to study the C3d:FH19â20 complex in atomic detail. NMR further identified glycosaminoglycan-binding residues in FH module 20 of the C3d:FH19â20 complex. Mutagenesis justified the merging of the C3d:FH19â20 structure with an existing C3b:FH1â4 crystal structure. The merged structure was concatenated with the available FH6â8 crystal structure and new SAXS-derived FH1â4, FH8â15 and FH15â19 envelopes. The combined data suggests a bent-back FH molecule, binding via its termini to two sites on one C3b molecule and simultaneously to adjacent polyanionic host-surface markers.</p>
      </abstract>
      <funding-group>
        <award-group>
          <funding-source country="United Kingdom">Wellcome Trust : </funding-source>
          <award-id>081179 || WT</award-id>
        </award-group>
      </funding-group>
    </article-meta>
  </front>
  <body>
    <p id="P6">The ~30 proteins of the complement system cooperate in a vital contribution to innate immunity <xref ref-type="bibr" rid="R1">1</xref>. The complement system is important for clearance of immune complexes and cellular debris, and for augmenting cell-based immunity, but is most famous for rapid targeting and elimination of pathogens. Host tissues may also sustain complement-mediated damage; several diseases, including age-related macular degeneration, atypical hemolytic uremic syndrome (aHUS) and dense deposit disease, link to mutations and single nucleotide polymorphisms (SNPs) in complement genes (reviewed in <xref ref-type="bibr" rid="R2">2</xref>).</p>
    <p id="P7">Key to the rapid responsiveness of complement is spontaneous, ubiquitous, low-level C3b production. In this âalternative pathwayâ (AP) of complement activation, cleavage of C3 to C3b is accompanied by a major rearrangement of its domains <xref ref-type="bibr" rid="R3">3</xref> (<xref ref-type="fig" rid="F1">Fig. 1</xref>). Notably, the thioester-containing domain (TED) migrates, rotates, and exposes its activated thioester thus allowing rapid attachment of C3b to nucleophiles on nearby particles, basement membranes or cell surfaces. C3b is both an important opsonin and a component of three out of four convertase complexes that drive the complement amplification cascade. For example, the bimolecular C3bBb complex, a C3 convertase, cleaves C3 to form more C3b (<xref ref-type="fig" rid="F1">Fig. 1</xref>), while the trimolecular (C3b)<sub>2</sub>Bb complex is a C5 convertase generating C5b thereby instigating the cytolytic terminal pathway of complement. Rigorous regulation is necessary to minimize complement-mediated damage to host.</p>
    <p id="P8">Complement factor H (FH) limits promulgation of C3b <xref ref-type="bibr" rid="R4">4</xref>-<xref ref-type="bibr" rid="R6">6</xref>, and this activity is essential to ensure the AP of complement activation operates in a manner that is both proportionate and targeted. This 155-kDa soluble glycoprotein consists exclusively of 20 complement control modules (CCPs) <xref ref-type="bibr" rid="R7">7</xref> (<xref ref-type="fig" rid="F1">Fig. 1</xref>), each containing approximately 60 amino acid residues. FH acts in the fluid phase and on self-surfaces and displays several related activities. It competes with complement factor B for binding to C3b thus blocking C3Bb formation and also accelerates the irreversible decay of any C3bBb that does form. Finally FH is a cofactor for factor I-mediated C3b cleavage to iC3b that cannot bind factor B. The iC3b fragment retains the intact TED and thus remains surface attached (<xref ref-type="fig" rid="F1">Fig. 1</xref>). The TED survives a series of further degradation steps that may occur resulting, sequentially, in surface-bound fragments, C3dg (~39 kDa)(prepro-C3 numbering 955â1303) and C3d (~34 kDa)(prepro-C3 numbering 996â1303); the latter corresponds almost precisely to the original TED and is a ligand for complement receptor type 2 (CR2), and thereby an adjuvant for humoral immunity.</p>
    <p id="P9">FH engages most effectively with C3b or C3bBb when these are attached to self-surfaces carrying specific polyanionic markers such as glycosaminoglycans (GAGs) and sialic acid <xref ref-type="bibr" rid="R8">8</xref>,<xref ref-type="bibr" rid="R9">9</xref>. The consequent enrichment of FH on such surfaces compared to its paucity on, for example, bacterial surfaces, helps innate immunity discriminate between host and pathogens. Two FH regions bind to C3b (<xref ref-type="fig" rid="F1">Fig. 1</xref>): the N-terminal four CCPs (FH1â4), which harbor the factor I cofactor and Bb decay acceleration activities; and, more strongly, the two C-terminal CCPs (FH19â20) <xref ref-type="bibr" rid="R10">10</xref>-<xref ref-type="bibr" rid="R13">13</xref>. The FH1â4:C3b interaction is well characterized <xref ref-type="bibr" rid="R14">14</xref> (<xref ref-type="fig" rid="F1">Fig. 1</xref>) while the FH19â20:C3b interaction is not. This is despite the presence in the FH C-terminus of a mutation cluster linked to the kidney disease aHUS <xref ref-type="bibr" rid="R15">15</xref>-<xref ref-type="bibr" rid="R17">17</xref> together with a polyanion-binding site required for self-surface recognition by FH <xref ref-type="bibr" rid="R18">18</xref>,<xref ref-type="bibr" rid="R19">19</xref>. These two C3b-binding sites of FH confer avidity <xref ref-type="bibr" rid="R12">12</xref> but the role of the intervening 14 CCPs remains controversial although CCP7 contains a second polyanion-binding site <xref ref-type="bibr" rid="R12">12</xref>,<xref ref-type="bibr" rid="R16">16</xref>,<xref ref-type="bibr" rid="R20">20</xref>,<xref ref-type="bibr" rid="R21">21</xref> and, intriguingly, harbors the SNP most strongly linked to the risk of developing age-related macular degeneration <xref ref-type="bibr" rid="R22">22</xref>-<xref ref-type="bibr" rid="R25">25</xref>.</p>
    <p id="P10">How these multiple binding sites for C3b and polyanions, located towards either end of the 20-CCP length of FH, cooperate to engage with C3b preferentially on a GAG-rich self-surface remains a mystery despite much effort. This dearth of knowledge impedes understanding of the role of FH mutants and sequence variants in disease. Here we show that a novel atomic-resolution crystal structure of the C3d:FH19â20 complex emulates the interaction between the FH C-terminus and C3b. We have combined this structure with further experimental data to build an insightful model of the complex formed by FH with C3b tethered to a self-surface.</p>
    <sec sec-type="results" id="S1">
      <title>RESULTS</title>
      <sec id="S2">
        <title>The crystal structure of C3:FH19â20 solved at 2.1-Ã resolution</title>
        <p id="P11">Useable co-crystals of C3d and FH19â20 were obtained at pH 7.0 and pH 9.0. In both cases the asymmetric unit contains three molecules each of FH19â20 and C3d. Although crystal packing was not identical, similar intermolecular interactions are observed in both crystal structures (<xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 1</xref>). The higher-pH structure has better resolution (2.1 Ã versus 3.5 Ã; <xref ref-type="table" rid="T1">Table 1</xref>) and is discussed further.</p>
        <p id="P12">A total of eight sets of heterotypic contacts were observed between FH19â20 molecules and C3d molecules in the crystal structure (<xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 1</xref>, <xref ref-type="supplementary-material" rid="SD1">Supplementary Tables 1-2</xref>), with the two most extensive sets being nearly identical. This duplicated interface â unlike others within the crystal structure â could correspond to the physiologically critical interface formed between the FH C-terminus and C3b: FH19â20 does not experience any steric clashes when this interface is extrapolated onto the corresponding TED domain of C3b (as judged from the multiple crystal structures of C3b <xref ref-type="bibr" rid="R3">3</xref>,<xref ref-type="bibr" rid="R14">14</xref>,<xref ref-type="bibr" rid="R26">26</xref>, see <xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 2</xref>); nor would it sterically hinder the functionally critical covalent linkage of C3d to biological surfaces, centered around Gln19 (Gln1013; prepro-C3 numbering indicated in parentheses hereon). Strikingly, this interface also correlates well with the distribution of a number of disease-associated variants of FH and C3 (discussed further below). The alternative complexes that might be inferred from other, less extensive, candidate interfaces in the crystal structure (<xref ref-type="supplementary-material" rid="SD1">Supplementary Tables 1-2</xref>) could not occur in the complex of FH with surface-bound C3b since they would involve significant steric clashes between FH19â20 and C3b, or they would mask the residues involved in surface tethering (<xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 2</xref>). Moreover, the distributions of disease-associated mutations within FH and C3 are inconsistent with the alternative interfaces. Further experimental validation of the physiologically relevant C3d:FH19â20 complex is described in detail below.</p>
        <p id="P13">Our structure confirms that discontinuous stretches of the FH19â20 polypeptide form a contiguous binding surface for C3d (<xref ref-type="fig" rid="F2">Fig. 2a,b</xref>; <xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 1</xref>) burying ~750 Ã<sup>2</sup> of surface area in total. The C-terminal half of C3d Î±-helix 4 (Î±4) contacts a region centered on Î²-strand B (Î²B) of FH CCP19 that also includes the hypervariable region following Î²B, the C-terminal part of Î²D, and the early part of the Î²D-Î²E loop. The Î±4-Î±5 loop of C3d protrudes, occupying the cleft between the two FH CCPs. Its side-chains contact Î²C in CCP20 as well as the intermodular linker. Also of note is substantial burial in the intermolecular interface of Tyr1190 (in CCP20) and van der Waals interactions between inter-modular linker residue Pro1166 and C3d-residue Prol121 (Pro1114 in C3). The N-terminal half of C3d Î±7 also participates: Lys178 (Lys1171) forms H-bonds with CCP19 residues Asn1117 and also with Gln1139 and Tyr1142 of the CCP19 Î²D-Î²E loop. Thus a network of side chain-backbone and side chain-side chain H-bonds and van der Waalsâ contacts (<xref ref-type="fig" rid="F2">Fig. 2c-d</xref>, <xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 1</xref>) stabilize the intermolecular interface that involves both modules 19 and 20 of FH.</p>
      </sec>
      <sec id="S3">
        <title>NMR identifies C3b-interacting segments in both modules 19 and 20</title>
        <p id="P14">NMR spectroscopy was used to independently address the C3d:FH19â20 complex. Following addition of (non-isotopically labeled) C3d a marked reduction of NH signal intensities occurred in the [<sup>1</sup>H,<sup>15</sup>N]-HSQC spectrum of <sup>15</sup>N-FH19â20 (<xref ref-type="fig" rid="F3">Fig 3</xref>;<xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 3</xref>). This reflects formation of the C3d:FH19â20 complex that would be expected to have slower molecular tumbling and shorter <italic>T</italic><sub>2</sub> relaxation times compared to FH19â20. No such changes were observed in a control in which <sup>15</sup>N-FH19 replaced <sup>15</sup>N-FH19â20 (not shown). Signal losses and concomitant line broadening were, however, not uniform during titration of <sup>15</sup>N-FH19â20. This indicates that, for selected residues, the overall relaxation rate contains a contribution from chemical exchange on the intermediate timescale. Such behavior is well documented <xref ref-type="bibr" rid="R27">27</xref>,<xref ref-type="bibr" rid="R28">28</xref>; it occurs for amides that exhibit larger chemical shift differences between bound and free forms. Corresponding residues very likely contribute directly to binding, or participate in conformational changes upon binding <xref ref-type="bibr" rid="R29">29</xref>,<xref ref-type="bibr" rid="R30">30</xref>.</p>
        <p id="P15">Eleven cross-peaks originally present in the <sup>15</sup>N-FH19â20 spectrum were broadened upon addition of C3d to the extent that they lost more than 90% of their signal intensities (<xref ref-type="fig" rid="F3">Fig. 3</xref>, <xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 3</xref>). Mapping the positions of these most strongly affected amides on the FH19â20 structure (<xref ref-type="fig" rid="F3">Fig. 3</xref>) provides strong evidence for the C3d-binding surface identified in the crystal-structure: Within CCP19, Î²-strand B (Î²B) (including Asp1119) and the first few residues of the Î²B-Î²C hypervariable loop plus the end of Î²D are implicated; within CCP20, Î²C appears to be involved. Only Tyr1177 and Ser1209 (whose signal loss was just above the 90% threshold) lie outside of this interaction region.</p>
      </sec>
      <sec id="S4">
        <title>Mutagenesis studies of the C3d:FH19â20 binding interface</title>
        <p id="P16">We combined new and existing mutagenesis data to corroborate our structural findings. Using surface plasmon resonance, we tested previously generated functionally critical mutations within the structure of FH19â20 <xref ref-type="bibr" rid="R31">31</xref> (<xref ref-type="fig" rid="F4">Fig. 4a-d</xref>). The FH mutation that was observed to have the most deleterious effect on the binding of FH to C3d and C3b, and that also abrogates activity in a hemolysis-protection assay, is D1119G within CCP19 (<xref ref-type="fig" rid="F4">Fig. 4c-e</xref>, <xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 4 and Supplementary Fig. 5</xref>); this is consistent with its key position in the interface identified from NMR and X-ray crystallography. A second key interface residue according to our X-ray crystallographic structure is Gln1139 of CCP19; in a previously reported mutagenesis study the Q1139A mutant of FH19â20 exhibited greatly reduced capacity to inhibit wild-type FH binding to C3d <xref ref-type="bibr" rid="R32">32</xref>. A number of other functionally significant mutations occupy several faces of CCP20 but do not appear to delineate a discrete binding surface (<xref ref-type="fig" rid="F4">Fig. 4d-f</xref>).</p>
        <p id="P17">Affinities were also measured between selected FH19â20 mutants and five C3d mutants (<xref ref-type="fig" rid="F4">Fig. 4g</xref>, <xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 4</xref>): E117A (E1110A), D122A (D1115A), and E117A D122A (E1110A D1115A) occupy the NMR and crystallography-derived interface, while E160A (E1153A) and I164A (I1157A) occur within the âconcaveâ surface of this molecule away from the putative FH19â20 binding site. Strikingly, our E117A D122A (E1110A D1115A) double mutation resulted in a decrease in affinity by a factor of ~1,600 (<xref ref-type="supplementary-material" rid="SD1">Supplementary Table 3</xref>; <xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 4</xref>). With regard to single mutants, in general (and with the exception of the aforementioned D1119G), loss of a positive charge in FH19â20 or loss of a negative charge in C3d decreased affinity, even away from the binding interface. However, it is noteworthy that the C3d single-site E117A (E1110A) and D122A (D1115A) mutations attenuate FH19â20 binding by a factor of two or three when compared to E160A and the non-charge substitution I164A, and by a factor of four to six when compared to wild-type C3d, respectively (<xref ref-type="supplementary-material" rid="SD1">Supplementary Table 3</xref>).</p>
        <p id="P18">Thus mutagenesis confirms that Glu117 (Glu1110) and Asp122 (Asp1115) in C3d and Asp1119 in CCP19 and Gln1139 in CCP19 are critical interface residues. Other charged residues explored in this study presumably participate in electrostatic steering effects. Such long-range charge effects have previously been reported for the interactions that occur between C3d and CR2, and between C3d and the staphylococcal immune evasion molecule Efb-C <xref ref-type="bibr" rid="R33">33</xref>,<xref ref-type="bibr" rid="R34">34</xref>.</p>
      </sec>
      <sec id="S5">
        <title>FH19â20 binds to both C3d and C3b in the same way</title>
        <p id="P19">We investigated whether structural information concerning the C3d:FH19â20 complex can be extrapolated to the physiologically important C3b:FH complex. We measured affinities for C3d (and, in some cases, for C3b) of FH15â19, FH18â20, FH19â20 and a panel of FH19â20 mutants (<xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 4</xref> and <xref ref-type="supplementary-material" rid="SD1">Supplementary Table 3</xref>). Affinities of FH18-20 and FH19â20 for C3d are similar (<xref ref-type="fig" rid="F4">Fig. 4a,b,d</xref> and <xref ref-type="supplementary-material" rid="SD1">Supplementary Table 3</xref>). Moreover, both bind equally well to C3b and C3d, while FH15â19 binds to neither C3d nor C3b (<xref ref-type="fig" rid="F4">Fig. 4d</xref> and <xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 4</xref>). Thus we further confirmed that both the C3b:FH and C3d:FH interfaces involve CCP19 and CCP20 (in good agreement with <xref ref-type="bibr" rid="R35">35</xref>), but not CCP18. Importantly, each of these FH19â20 mutants binds similarly well, or similarly poorly, to both C3d (<xref ref-type="fig" rid="F4">Fig. 4d</xref> and <xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 4</xref>) and C3b (based on <italic>K</italic><sub>D</sub> values reported by <xref ref-type="bibr" rid="R31">31</xref>). Notably, FH19â20 D1119G binds to neither of these C3 fragments (<xref ref-type="fig" rid="F4">Fig. 4c</xref> and <xref ref-type="bibr" rid="R31">31</xref>). A comparison of the mutagenesis data, summarized in <xref ref-type="fig" rid="F4">Figures 4e and 4f</xref>, thus illustrates that the C3d:FH19â20 interface must emulate the interface that is found between the C-terminus of FH and C3b. A logical extension of this finding is that the site in C3d that interacts with FH19â20 must correspond to an accessible face of the TED within the C3b. As outlined above, this requirement is met by the C3d:FH19â20 interface identified by both NMR and crystallography.</p>
      </sec>
      <sec id="S6">
        <title>Extrapolation to a C3b:FH1â4:FH19â20 complex</title>
        <p id="P20">The very good superposition of the C3d polypeptide within the C3d:FH19â20 complex onto the relevant residues of the TED domain within the crystal structure of the C3b:FH1â4 complex (PDB accession code: 2WII <xref ref-type="bibr" rid="R14">14</xref>) is shown in <xref ref-type="fig" rid="F5">Figure 5</xref>. The resulting merged model of a ternary complex of C3b with two segments of FH suggests that CCP19 of FH19â20 lies immediately adjacent to CCP4 of FH1â4 but that the two fragments occupy distinct regions of C3b consistent with simultaneous binding. The merged model also suggests that, in the complex, the majority of CCP20 is exposed, and positioned to interact with polyanionic surface markers.</p>
      </sec>
      <sec id="S7">
        <title>CCP20 within C3d-bound FH19â20 recognizes surface-associated GAG molecules</title>
        <p id="P21">Experiments were performed to ascertain whether CCP20 within the C3d:FH19â20 complex can still engage with model GAGs (that are surrogates for self-surface markers), and to identify which FH residues are critical to GAG-binding.</p>
        <p id="P22">In initial benchmarking work, an octasaccharide fraction of heparin, dp8, was titrated into <sup>15</sup>N-labeled FH19â20 (<italic>i.e.</italic> no C3d present) (<xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 3</xref>). The largest chemical-shift changes (brought about by an 8.5-fold dp8:FH19â20 ratio) (<xref ref-type="fig" rid="F3">Fig. 3c</xref>) occur in residues that belonging to CCP20. The distribution of affected residues (<xref ref-type="fig" rid="F5">Fig. 5</xref>), is consistent with two (or more) dp8 molecules binding with similar affinities to electropositive patches around Lys1186âLys1188, and Arg1231; this agrees with a previous NMR study on FH19â20 performed with a tetrasaccharide heparin fragment <xref ref-type="bibr" rid="R16">16</xref>.</p>
        <p id="P23">Titration with up to a 15-fold excess of dp8 into the C3d:<sup>15</sup>N-FH19â20 complex caused chemical shift changes but, importantly, did not alter spectral intensities or line-widths (<xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 3</xref>). In separate experiments, a 20-fold excess (over FH19â20) of a pentasaccharide GAG (Fondaparinux) did not inhibit FH19â20 binding to amine-coupled C3d according to SPR (<xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 4</xref>); furthermore molar excesses of up to 200-fold (over C3d) of dp8 failed to inhibit C3d binding to FH19â20 in an ELISA-based assay (<xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 6</xref>). All these experiments support the existence of a ternary (or higher order) complex formed between C3d, FH19â20 and GAGs.</p>
        <p id="P24">It is notable that the subset of FH19â20 NH resonances experiencing substantial dp8-induced chemical shift changes is essentially the same whether FH19â20 is in complex with C3d or not (compare <xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 3b and Supplementary Fig. 3c</xref>). The amide resonances of some CCP20 residues (exemplified by Lys1188) previously implicated in C3d binding remain very weak when GAGs are added, consistent with C3d proximity; but they still exhibit GAG-associated chemical-shift perturbations similar to those observed in the absence of C3d, which is consistent with GAG-binding and ternary complex formation. While a mixture of binary and tertiary complexes may be present in the NMR tube we can nevertheless conclude that at least one dp8 molecule binds to the C3d:FH19â20 complex at a region of CCP20 distinct from the C3d-binding site (<xref ref-type="fig" rid="F5">Fig. 5</xref>) and proximal to the surface to which C3d/TED is tethered. Our data are in excellent agreement with previous studies in which K1186A, K1188A, K1188Q, L1189R and K1230A FH19â20 mutants, amongst others, were shown to have altered heparin affinity <xref ref-type="bibr" rid="R31">31</xref>,<xref ref-type="bibr" rid="R32">32</xref>. Thus the GAG-binding face originally delineated by FH19â20 chemical shift perturbations in the absence of C3d <xref ref-type="bibr" rid="R16">16</xref>, is now shown to also exist in the C3d:FH19â20 complex.</p>
      </sec>
      <sec id="S8">
        <title>Factor H bends back to allow both termini to interact with C3b</title>
        <p id="P25">In the modeled ternary complex of C3b, FH1â4 and FH19â20, the C-terminus of CCP4 and the N-terminus of CCP19 lie close together on the same side of C3b, but importantly, do not clash (<xref ref-type="fig" rid="F5">Fig. 5a-c</xref>). This is consistent with a 1:1 complex of C3b and FH in which intervening FH CCP modules form a compact bent-back structure (<xref ref-type="fig" rid="F5">Fig. 5b</xref>), or with a 1:2 FH:C3b complex in which a more extended single FH molecule bridges two C3b molecules. To complement the available incomplete experimental evidence on FH architecture <xref ref-type="bibr" rid="R36">36</xref>-<xref ref-type="bibr" rid="R38">38</xref>, we collected SAXS curves for FH1â4, FH8â15 and FH15â19, and performed <italic>ab initio</italic> shape calculations (<xref ref-type="fig" rid="F5">Fig. 5b</xref>, <xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 7</xref>). The resulting <italic>ab initio</italic> model of FH1â4 is in excellent agreement with the corresponding crystal structure <xref ref-type="bibr" rid="R14">14</xref>, while the FH8â15 and FH15â19 shape envelopes (for which no structures are available) describe a relatively compact bent-back structure, and an extended rod-like structure, respectively. The compact shape of FH8â15 model (as previously described also for both FH10â15 and FH11â14 <xref ref-type="bibr" rid="R37">37</xref>) involves significant intermodular contacts that could stabilize bent-back structures for both free and C3b-bound full-length FH. By manually concatenating our SAXS-derived envelopes for FH8â15 and FH15â19 with the X-ray derived structures of FH6â8 <xref ref-type="bibr" rid="R36">36</xref> and C3d:FH19â20 it was possible to model FH modules 6â20 in complex with C3b (<xref ref-type="fig" rid="F5">Fig. 5b</xref>). This model was readily adjusted so that CCP6 and the C-terminus of CCP4 (in the C3b:FH1â4 complex overlaid via TED on C3d) are separated by a space large enough to be spanned by the known structure of CCP5 <xref ref-type="bibr" rid="R39">39</xref> thus creating a model of a 1:1 C3b:FH complex.</p>
      </sec>
    </sec>
    <sec sec-type="discussion" id="S9">
      <title>DISCUSSION</title>
      <p id="P26">Here we illuminate how FH binds to its principal target. This crucial event in regulation of C3b promulgation on self-surfaces is central to protection of host tissues from complement-mediated damage. Building on previous indications that FH19â20 binds to both C3b and the C3b-derived fragment, C3d <xref ref-type="bibr" rid="R32">32</xref>, we showed that the C3d:FH19â20 interaction is a surrogate for the less experimentally accessible FH:C3b interaction. Our new observations, when combined with published data, show how the FH molecule bends back on itself such that its N terminus performs cofactor and decay accelerating activities while the C terminus recognizes a composite consisting of the TED of C3b and nearby polyanionic carbohydrates. This allows distinction of a self-surface from most bacterial ones.</p>
      <p id="P27">Mindful of controversy surrounding the physiological validity of a crystal structure of C3d complexed with CR2 CCP1-2 <xref ref-type="bibr" rid="R40">40</xref>, we employed mutagenesis and NMR to select the physiologically relevant intermolecular interface from several possibilities within our crystal structure of C3d:FH19â20. Moreover this interface of C3d is consistent with other observations. <italic>(i)</italic> It is accessible in TED (<italic>i.e.</italic> within the context of C3b) tethered to a surface; moreover the orientation of FH19â20 means that CCP18 is projected clear of C3b, consistent with our finding that it binds neither C3d nor C3b (<xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 4</xref> and <xref ref-type="supplementary-material" rid="SD1">Supplementary Table 3</xref>). <italic>(ii)</italic> It does not overlap the FH1â4 interaction site on C3b <xref ref-type="bibr" rid="R14">14</xref>, consistent with avidity between sites <xref ref-type="bibr" rid="R12">12</xref>. <italic>(iii)</italic> It is directly adjacent to (but non-overlapping with) the Efb-C-binding site <xref ref-type="bibr" rid="R41">41</xref> (<xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 8</xref>); this is important because Efb-C enhances binding of C3b to FH19â20 <xref ref-type="bibr" rid="R42">42</xref>. <italic>(iv)</italic> The C3d and FH residues involved are conserved (<xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 9</xref>).</p>
      <p id="P28">We confirmed that previously identified GAG-binding residues of CCP20 are still accessible within this complex. This is compelling structural evidence for the hypothesis that FH19â20 interacts with a composite site consisting of the TED and proximal polyanions. Previous attempts to dock C3d onto the surface of FH19â20 now prove to have been unsuccessful <xref ref-type="bibr" rid="R16">16</xref>,<xref ref-type="bibr" rid="R43">43</xref>. In both of these models of C3d:FH19â20, only CCP20 makes contact with C3d; moreover the interfaces on C3d differ from that identified in our co-crystal structure.</p>
      <p id="P29">Our new data reveal locations, relative to key interaction surfaces, of disease-linked mutations and sequence variations (<xref ref-type="fig" rid="F6">Fig. 6</xref>). Our structure explains the key role in C3b binding we observed for the disease-linked mutation D1119G, despite suggestions from others that this mutation is functionally null <xref ref-type="bibr" rid="R32">32</xref>. Our complex also shows that the following aHUS-linked FH mutations <xref ref-type="bibr" rid="R44">44</xref> affect the C3d:FH19â20 interface and thereby perturb the fine balance of affinities needed for proper FH operation: Y1142D and Y1142C, since Tyr1142 H-bonds to C3dâs Lys178 (Lys1171); Q1143E due to its proximity to Tyr1142; L1189F, L1189R and S1191L, since Tyr1190 H-bonds to Asp122 (Asp1115) of C3d and is partially buried at the interface. Other aHUS-linked FH mutations are in the GAG-binding regions of CCP20 and/or could disrupt putative electrostatic steering events (E1198A, R1203A, R1210C, R1215G, R1182S, W1183R and T1184R). Another subset of aHUS-linked FH mutants likely promotes structural perturbations (W1157R, V1134G, G1194D, V1197A, F1199S and P1226S). Regarding the C3b side of the interaction, the following aHUS-linked mutations likely disrupt the binding interface: P121L (P1114L) <xref ref-type="bibr" rid="R45">45</xref> and D122N (D1115N) <xref ref-type="bibr" rid="R46">46</xref> are in the C3d Î±4-Î±5 loop occupying the FH19â20 intermodular cleft; C165W (C1158W) and Q168K (Q1161K) <xref ref-type="bibr" rid="R46">46</xref> are in the C3d Î±6âÎ±7 loop that, intriguingly, coincides with closest approach of the N-terminal and C-terminal C3b-binding sites of FH (<xref ref-type="fig" rid="F5">Fig. 5c</xref>).</p>
      <p id="P30">In a previously solved structure of the FH1â4:C3b complex <xref ref-type="bibr" rid="R14">14</xref>, the four N-terminal CCPs of FH form an elongated contact with C3b running largely parallel with the long axis of C3b. If C3b in this complex were surface-attached via its thioester, CCP1 would be furthest, and CCP4 closest, to that surface. In other AP regulators, a similar three-CCP or four-CCP C3b-binding segment is connected to a C-terminal transmembrane helix or a GPI anchor, which localizes the regulator upon a cell surface requiring protection from C3b promulgation. FH is not constrained to a membrane but relies on some or all of its C-terminal 16 CCPs for localization, and exploits the preponderance of polyanionic self-surface markers to selectively increase its residency time on self-surfaces. We investigated the path taken by CCPs 5-18, which connect N-terminal and C-terminal C3b-binding sites, to construct an experimentally derived model of the FH:C3b complex.</p>
      <p id="P31">When the C3d of C3d:FH19â20 is superimposed on the TED of C3b, the FH1â4 C-terminus and FH19â20 N-terminus are close together. A bent-back FH structure would therefore be required were a single molecule to simultaneously occupy both sites on C3b (and interact with self-surface associated polyanions), as in our model (<xref ref-type="fig" rid="F5">Fig. 5a</xref>). This is fully consistent with our SAXS-derived shape-envelopes of FH fragments presented here, as well as with existing SAXS, crystal and NMR-derived structures, and agrees with previous work showing that non-liganded FH could adopt a predominantly bent-back conformation <xref ref-type="bibr" rid="R37">37</xref>,<xref ref-type="bibr" rid="R47">47</xref>-<xref ref-type="bibr" rid="R50">50</xref>. Our data are incompatible with an alternative model in which FH wraps around the C3b molecule. However, we cannot exclude the existence of a complex in which one FH molecule binds to two neighboring, closely packed, C3b molecules.</p>
      <p id="P32">Previous studies suggested a weak additional C3b-binding site within FH CCPs 6â8 <xref ref-type="bibr" rid="R12">12</xref>,<xref ref-type="bibr" rid="R13">13</xref>. While no such interface exists within our model of the complex, uncertainties in reconstruction of the N-terminal half of FH (lacking structural information for FH4â5/FH5â6) means we cannot exclude CCP6/7-C3b contacts. Nonetheless, our model places CCP7 close to the self-surface where it could recognize additional GAG surface markers; it also places the structurally deviant module, CCP13 <xref ref-type="bibr" rid="R37">37</xref> close to the self-surface, although the nature of any ligand for CCP13 remains undetermined.</p>
      <p id="P33">In summary, we present an experimentally supported structural model for how a FH molecule engages bivalently with a C3b molecule and simultaneously with self-surface polyanionic markers. The model indicates that effective complement inhibitors, with therapeutic potential, might be constructed through flexible linkage of FH19â20, via a domain with appropriately apposed N and C termini, to FH1â4 or homologous segments of other complement regulators.</p>
    </sec>
    <sec sec-type="methods" id="S10">
      <title>METHODS</title>
      <p id="P34">Methods and any associated references are available in the online version of the paper at <ext-link ext-link-type="uri" xlink:href="http://www.nature.com/nsmb/">http://www.nature.com/nsmb/</ext-link>.</p>
    </sec>
    <sec sec-type="supplementary-material" id="SM">
      <title>Supplementary Material</title>
      <supplementary-material content-type="local-data" id="SD1">
        <label>1</label>
        <media xlink:href="NIHMS34061-supplement-1.pdf" xlink:type="simple" id="d36e804" position="anchor" mimetype="application" mime-subtype="pdf"/>
      </supplementary-material>
    </sec>
  </body>
  <back>
    <ack id="S11">
      <title>ACKNOWLEDGEMENTS</title>
      <p>Use of the Protein Production Facilities at the University of Edinburgh was supported by The Wellcome Trust, the Scottish University Life Sciences Alliance and the BBSRC. A.P.H was supported by Wellcome Trust (078780/Z/05/Z to D.U. and P.N.B.), B.S.B was supported by EastChem PhD studentship and a University of Edinburgh campaign small project grant, C.M.J was supported by EC FP6 (Marie Curie EST Fellowship, contract: MEST-CT-2005-020744).</p>
    </ack>
    <fn-group>
      <fn id="FN3">
        <p id="P44"><bold>Accession codes.</bold> Protein Data Bank: Coordinates and structure factors for the C3d:FH19â20 complex have been deposited under accession number 3OXU.</p>
      </fn>
      <fn id="FN4">
        <p id="P45">Note: <xref ref-type="supplementary-material" rid="SD1">Supplementary information</xref> is available on the Nature Structural &amp; Molecular Biology website.</p>
      </fn>
    </fn-group>
    <app-group>
      <app id="APP1">
        <title>APPENDIX</title>
        <sec id="S12">
          <title>ONLINE METHODS</title>
          <sec id="S13">
            <title>FH1â4, FH8â15, FH15â18, FH15â19 and FH18-20 and FH19â20 Protein Production</title>
            <p id="P35">Recombinant wild-type forms of human FH1â4, FH8â15 and wild-type and mutant forms of FH19â20 were produced utilizing a <italic>Pichia pastoris</italic> expression system as previously described <xref ref-type="bibr" rid="R12">12</xref>,<xref ref-type="bibr" rid="R16">16</xref>,<xref ref-type="bibr" rid="R31">31</xref>. Resulting recombinant forms of FH were secreted into the media and purified by successive ion exchange and size exclusion chromatography steps. Additional CCP15â18, CCP15â19 and CCP18â20 constructs of human FH were also engineered utilizing a FH codon-optimized gene and cloned into the <italic>Pichia pastoris</italic> pPICZÎ±B expression vector (Invitrogen). Recombinant forms of these proteins were generated and purified as outlined above for FH1â4, FH8â15 and FH19â20.</p>
          </sec>
          <sec id="S14">
            <title>Wild-type and mutant C3d production</title>
            <p id="P36">Recombinant wild-type, E117A (prepro C3 numbering: E1110A), D122A (D1115A), E117A/D122A (E1110A/D1115A), E160A (E1153A) and I164A (I1157A) mutant forms of C3d, corresponding to residues 996â1306 of wild-type human C3d (C3d<sub>996-1306</sub>), and containing an additional C17A (C1011A) point mutation, were produced utilizing an <italic>Escherichia coli</italic> expression system as previously described <xref ref-type="bibr" rid="R52">52</xref>,<xref ref-type="bibr" rid="R53">53</xref>. GST-tagged forms of this protein were obtained as described in the <bold><xref ref-type="supplementary-material" rid="SD1">Supplementary Methods</xref></bold>.</p>
          </sec>
          <sec id="S15">
            <title>Analysis of wild-type and mutant FH binding by surface plasmon resonance (SPR)</title>
            <p id="P37">Surface plasmon resonance was used to determine the binding affinity of wild-type and mutant forms of FH19â20 (D1119G, R1182S, W1183L, W1183R, T1184R, L1189F, L1189R, S1191L, S1191L-V1197A, V1197A, R1203S, R1210C, R1215Q), and wild-type FH15â18, FH15â19 and FH18â20 to amine-coupled and physiologically-immobilized forms of wild-type C3d and C3dg, respectively, as described in the <bold><xref ref-type="supplementary-material" rid="SD1">Supplementary Methods</xref></bold>. Binding analyses under identical solution conditions were also carried out utilizing immobilized recombinant mutant forms of C3d (E117A, (E1110A) D122A (D1115A), E117A D122A (E1110 D1115A), E160A (E1153A) and I164A (I1157A)), and wild-type and R1182S, L1189F, L1189R and R1215Q variant forms of FH19â20. Binding of C3b to FH15â19, and FH18-20 were carried out under identical conditions to those described above. To demonstrate that the GAG-binding site of FH CCP20 does not overlap with the FH19â20 binding site on C3d, SPR was also used to determine the binding affinity of wild-type FH19â20 to amine-coupled recombinant C3d in the presence of a 20-fold excess of the pentasaccharide GAG-surrogate, Fondaparinux (kindly donated by GlaxoSmithKline PLC, U.K) (<bold>see <xref ref-type="supplementary-material" rid="SD1">Supplementary Methods</xref></bold>).</p>
          </sec>
          <sec id="S16">
            <title>Crystallization and data collection</title>
            <p id="P38">Crystals of C3d in complex with FH19â20 were grown at 17 Â°C by the vapor diffusion method from hanging drops. Drops contained an equal volume of a protein solution in which a complex had been formed with a 1:1 molar ration of C3d:FH19â20 in phosphate buffered saline, pH 7.4 (PBS: 137 mM NaCl, 8.1 mM Na<sub>2</sub>HPO<sub>4</sub>, 2.7 mM KCl, 1.5 mM KH<sub>2</sub>PO<sub>4</sub>), with an equal volume of well solution. Well solution conditions for the C3d:FH19â20 complex were 0.1 M Tris-HCl, pH 9.0, 8% w/v PEG 8K. Prior to data collection, crystals were cryoprotected with well solution additionally containing 25% v/v glycerol (added stepwise), mounted in loops and flash frozen in liquid nitrogen at 77K. Additional crystals of the C3d:FH19â20 complex were also grown at pH 7.0 as described in the <bold><xref ref-type="supplementary-material" rid="SD1">Supplementary Methods</xref></bold>. Intensity data were collected (Phi scans were 1Â° over 360Â°) at the Diamond synchrotron radiation facility in Oxfordshire, United Kingdom on beamlines I02, I03 and I04. Data were then processed in the P1 space group with MOSFLM <xref ref-type="bibr" rid="R54">54</xref> and scaled with SCALA <xref ref-type="bibr" rid="R55">55</xref>. The P1 space-group was confirmed using the program POINTLESS and there was no indication of non-crystallographic symmetry by self rotation function analysis <xref ref-type="bibr" rid="R55">55</xref>.</p>
          </sec>
          <sec id="S17">
            <title>C3d:FH19â20 Structure determination</title>
            <p id="P39">The structure of the C3d:FH19â20 complex was solved by molecular replacement using the program PHASER <xref ref-type="bibr" rid="R56">56</xref>, with the previously determined structure of FH (PDB accession code: 2G7I <xref ref-type="bibr" rid="R43">43</xref>) and C3d (PDB accession code: 1C3D) <xref ref-type="bibr" rid="R57">57</xref>) as search models. There was a clear molecular replacement solution, with three C3d and three FH monomers in the crystallographic asymmetric unit. The initial model was subjected to ten cycles of restrained refinement using the program <italic>REFMAC</italic>
<xref ref-type="bibr" rid="R58">58</xref> resulting in R/R<sub>free</sub> values of 37.85 and 41.22, respectively. Module 20 of FH19â20 (Chain F) was removed at this stage of refinement as there was no clear interpretable electron density. Using the program COOT <xref ref-type="bibr" rid="R59">59</xref>, alternative side chain conformers were constructed and additional residues were added to the N- and C-terminal. The model was then subjected to several rounds of restrained refinement, resulting in R/R<sub>free</sub> values of 32.4 and 35.8, respectively. With the improvement of phases, <italic>F<sub>o</sub>-F<sub>c</sub></italic> electron density corresponding to module 20 of FHÂ·19-20 (Chain F) appeared, allowing for manual building and completion of this module. Areas of disorder were carefully modeled into <italic>F<sub>o</sub>-F<sub>c</sub></italic> electron density and the changes in R/R<sub>free</sub> values were used to assess final model quality. Water molecules were then added to the model using the program PHENIX and after several rounds of refinement the R/R<sub>free</sub> values converged to 17.06/20.59, respectively (<xref ref-type="table" rid="T1">Table 1</xref>). The geometry of the model was assessed using MolProbity <xref ref-type="bibr" rid="R60">60</xref> and the coordinates for the 2.1 Ã structure have been deposited in the Protein Data Bank with the code 3OXU. Superimpositions of structures were performed using Pymol. Also see <bold><xref ref-type="supplementary-material" rid="SD1">Supplementary Methods</xref>.</bold></p>
          </sec>
          <sec id="S18">
            <title>Glycosaminoglycan (GAG) preparation</title>
            <p id="P40">Heparin-derived octasaccharides were prepared as outlined in the <bold><xref ref-type="supplementary-material" rid="SD1">Supplementary Methods</xref>.</bold></p>
          </sec>
          <sec id="S19">
            <title>Hemolysis assay</title>
            <p id="P41">Ability of recombinant wild-type and D1119G forms of FH19â20 to inhibit FH mediated protection of sheep erythrocytes was measured as outlined in the <bold><xref ref-type="supplementary-material" rid="SD1">Supplementary Methods</xref>.</bold></p>
          </sec>
          <sec id="S20">
            <title>Nuclear Magnetic Resonance of the C3d:FH19â20 complex and FH19â20:GAG interactions</title>
            <p id="P42">C3d for the NMR study was purchased from Complement Technology (Texas) and <sup>15</sup>N-labeled FH19â20 was prepared as described previously <xref ref-type="bibr" rid="R16">16</xref>. All [<sup>1</sup>H, <sup>15</sup>N]-HSQC spectra were collected at 25 Â°C on a Bruker Avance 800 MHz NMR spectrometer equipped with a cryogenic TCI probe as described in the <bold><xref ref-type="supplementary-material" rid="SD1">Supplementary Methods</xref></bold>.</p>
          </sec>
          <sec id="S21">
            <title>Small-angle X-ray scattering, <italic>ab initio</italic> shape determination and molecular modelling</title>
            <p id="P43">Synchrotron radiation X-ray scattering data of recombinantly expressed-forms of FH1â4, FH8-15 and FH15-19 were collected, processed and these data together with existing three-dimensional FH structural data were utilized to generate a composite full-length FH:C3b model as set out in the <bold><xref ref-type="supplementary-material" rid="SD1">Supplementary Methods</xref></bold>.</p>
          </sec>
        </sec>
      </app>
    </app-group>
    <ref-list>
      <title>REFERENCES</title>
      <ref id="R1">
        <label>1</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ricklin</surname><given-names>D</given-names></name><name><surname>Hajishengallis</surname><given-names>G</given-names></name><name><surname>Yang</surname><given-names>K</given-names></name><name><surname>Lambris</surname><given-names>JD</given-names></name></person-group>
<article-title>Complement: a key system for immune surveillance and homeostasis</article-title>
<source>Nat. Immunol</source>
<year>2010</year>
<volume>11</volume>
<fpage>785</fpage>
<lpage>97</lpage>
<pub-id pub-id-type="pmid">20720586</pub-id></element-citation>
      </ref>
      <ref id="R2">
        <label>2</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>de Cordoba</surname><given-names>SR</given-names></name><name><surname>de Jorge</surname><given-names>EG</given-names></name></person-group>
<article-title>Translational mini-review series on complement factor H: genetics and disease associations of human complement factor H</article-title>
<source>Clin. Exp. Immunol</source>
<year>2008</year>
<volume>151</volume>
<fpage>1</fpage>
<lpage>13</lpage>
<pub-id pub-id-type="pmid">18081690</pub-id></element-citation>
      </ref>
      <ref id="R3">
        <label>3</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Janssen</surname><given-names>BJ</given-names></name><name><surname>Christodoulidou</surname><given-names>A</given-names></name><name><surname>McCarthy</surname><given-names>A</given-names></name><name><surname>Lambris</surname><given-names>JD</given-names></name><name><surname>Gros</surname><given-names>P</given-names></name></person-group>
<article-title>Structure of C3b reveals conformational changes that underlie complement activity</article-title>
<source>Nature</source>
<year>2006</year>
<volume>444</volume>
<fpage>213</fpage>
<lpage>6</lpage>
<pub-id pub-id-type="pmid">17051160</pub-id></element-citation>
      </ref>
      <ref id="R4">
        <label>4</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pangburn</surname><given-names>MK</given-names></name><name><surname>Schreiber</surname><given-names>RD</given-names></name><name><surname>Muller-Eberhard</surname><given-names>HJ</given-names></name></person-group>
<article-title>Human complement C3b inactivator: isolation, characterization, and demonstration of an absolute requirement for the serum protein beta1H for cleavage of C3b and C4b in solution</article-title>
<source>J. Exp. Med</source>
<year>1977</year>
<volume>146</volume>
<fpage>257</fpage>
<lpage>70</lpage>
<pub-id pub-id-type="pmid">301546</pub-id></element-citation>
      </ref>
      <ref id="R5">
        <label>5</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Weiler</surname><given-names>JM</given-names></name><name><surname>Daha</surname><given-names>MR</given-names></name><name><surname>Austen</surname><given-names>KF</given-names></name><name><surname>Fearon</surname><given-names>DT</given-names></name></person-group>
<article-title>Control of the amplification convertase of complement by the plasma protein beta1H</article-title>
<source>Proc. Natl. Acad. Sci. USA</source>
<year>1976</year>
<volume>73</volume>
<fpage>3268</fpage>
<lpage>72</lpage>
<pub-id pub-id-type="pmid">1067618</pub-id></element-citation>
      </ref>
      <ref id="R6">
        <label>6</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Whaley</surname><given-names>K</given-names></name><name><surname>Ruddy</surname><given-names>S</given-names></name></person-group>
<article-title>Modulation of the alternative complement pathways by beta 1 H globulin</article-title>
<source>J. Exp. Med</source>
<year>1976</year>
<volume>144</volume>
<fpage>1147</fpage>
<lpage>63</lpage>
<pub-id pub-id-type="pmid">62817</pub-id></element-citation>
      </ref>
      <ref id="R7">
        <label>7</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ripoche</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Partial characterization of human complement factor H by protein and cDNA sequencing: homology with other complement and non-complement proteins</article-title>
<source>Biosci. Rep</source>
<year>1986</year>
<volume>6</volume>
<fpage>65</fpage>
<lpage>72</lpage>
<pub-id pub-id-type="pmid">2938641</pub-id></element-citation>
      </ref>
      <ref id="R8">
        <label>8</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Meri</surname><given-names>S</given-names></name><name><surname>Pangburn</surname><given-names>MK</given-names></name></person-group>
<article-title>Regulation of alternative pathway complement activation by glycosaminoglycans: specificity of the polyanion binding site on factor H</article-title>
<source>Biochem. Biophys. Res. Commun</source>
<year>1994</year>
<volume>198</volume>
<fpage>52</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="pmid">8292049</pub-id></element-citation>
      </ref>
      <ref id="R9">
        <label>9</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pangburn</surname><given-names>MK</given-names></name></person-group>
<article-title>Host recognition and target differentiation by factor H, a regulator of the alternative pathway of complement</article-title>
<source>Immunopharmacology</source>
<year>2000</year>
<volume>49</volume>
<fpage>149</fpage>
<lpage>57</lpage>
<pub-id pub-id-type="pmid">10904114</pub-id></element-citation>
      </ref>
      <ref id="R10">
        <label>10</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gordon</surname><given-names>DL</given-names></name><name><surname>Kaufman</surname><given-names>RM</given-names></name><name><surname>Blackmore</surname><given-names>TK</given-names></name><name><surname>Kwong</surname><given-names>J</given-names></name><name><surname>Lublin</surname><given-names>DM</given-names></name></person-group>
<article-title>Identification of complement regulatory domains in human factor H</article-title>
<source>J. Immunol</source>
<year>1995</year>
<volume>155</volume>
<fpage>348</fpage>
<lpage>56</lpage>
<pub-id pub-id-type="pmid">7541419</pub-id></element-citation>
      </ref>
      <ref id="R11">
        <label>11</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pangburn</surname><given-names>MK</given-names></name></person-group>
<article-title>Cutting edge: localization of the host recognition functions of complement factor H at the carboxyl-terminal: implications for hemolytic uremic syndrome</article-title>
<source>J. Immunol</source>
<year>2002</year>
<volume>169</volume>
<fpage>4702</fpage>
<lpage>6</lpage>
<pub-id pub-id-type="pmid">12391176</pub-id></element-citation>
      </ref>
      <ref id="R12">
        <label>12</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>CQ</given-names></name><etal/></person-group>
<article-title>A new map of glycosaminoglycan and C3b binding sites on factor H</article-title>
<source>J. Immunol</source>
<year>2008</year>
<volume>181</volume>
<fpage>2610</fpage>
<lpage>2619</lpage>
<pub-id pub-id-type="pmid">18684951</pub-id></element-citation>
      </ref>
      <ref id="R13">
        <label>13</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sharma</surname><given-names>AK</given-names></name><name><surname>Pangburn</surname><given-names>MK</given-names></name></person-group>
<article-title>Identification of three physically and functionally distinct binding sites for C3b in human complement factor H by deletion mutagenesis</article-title>
<source>Proc. Natl. Acad. Sci. USA</source>
<year>1996</year>
<volume>93</volume>
<fpage>10996</fpage>
<lpage>1001</lpage>
<pub-id pub-id-type="pmid">8855297</pub-id></element-citation>
      </ref>
      <ref id="R14">
        <label>14</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wu</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Structure of complement fragment C3b-factor H and implications for host protection by complement regulators</article-title>
<source>Nat. Immunol</source>
<year>2009</year>
<volume>10</volume>
<fpage>728</fpage>
<lpage>33</lpage>
<pub-id pub-id-type="pmid">19503104</pub-id></element-citation>
      </ref>
      <ref id="R15">
        <label>15</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Buddles</surname><given-names>MR</given-names></name><name><surname>Donne</surname><given-names>RL</given-names></name><name><surname>Richards</surname><given-names>A</given-names></name><name><surname>Goodship</surname><given-names>J</given-names></name><name><surname>Goodship</surname><given-names>TH</given-names></name></person-group>
<article-title>Complement factor H gene mutation associated with autosomal recessive atypical hemolytic uremic syndrome</article-title>
<source>Am. J. Hum. Genet</source>
<year>2000</year>
<volume>66</volume>
<fpage>1721</fpage>
<lpage>2</lpage>
<pub-id pub-id-type="pmid">10762557</pub-id></element-citation>
      </ref>
      <ref id="R16">
        <label>16</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Herbert</surname><given-names>AP</given-names></name><name><surname>Uhrin</surname><given-names>D</given-names></name><name><surname>Lyon</surname><given-names>M</given-names></name><name><surname>Pangburn</surname><given-names>MK</given-names></name><name><surname>Barlow</surname><given-names>PN</given-names></name></person-group>
<article-title>Disease-associated sequence variations congregate in a polyanion recognition patch on human factor H revealed in three-dimensional structure</article-title>
<source>J. Biol. Chem</source>
<year>2006</year>
<volume>281</volume>
<fpage>16512</fpage>
<lpage>16520</lpage>
<pub-id pub-id-type="pmid">16533809</pub-id></element-citation>
      </ref>
      <ref id="R17">
        <label>17</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Perez-Caballero</surname><given-names>D</given-names></name><etal/></person-group>
<article-title>Clustering of missense mutations in the C-terminal region of factor H in atypical hemolytic uremic syndrome</article-title>
<source>Am. J. Hum. Genet</source>
<year>2001</year>
<volume>68</volume>
<fpage>478</fpage>
<lpage>84</lpage>
<pub-id pub-id-type="pmid">11170895</pub-id></element-citation>
      </ref>
      <ref id="R18">
        <label>18</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ferreira</surname><given-names>VP</given-names></name><name><surname>Herbert</surname><given-names>AP</given-names></name><name><surname>Hocking</surname><given-names>HG</given-names></name><name><surname>Barlow</surname><given-names>PN</given-names></name><name><surname>Pangburn</surname><given-names>MK</given-names></name></person-group>
<article-title>Critical role of the C-terminal domains of factor H in regulating complement activation at cell surfaces</article-title>
<source>J. Immunol</source>
<year>2006</year>
<volume>177</volume>
<fpage>6308</fpage>
<lpage>16</lpage>
<pub-id pub-id-type="pmid">17056561</pub-id></element-citation>
      </ref>
      <ref id="R19">
        <label>19</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jokiranta</surname><given-names>TS</given-names></name><etal/></person-group>
<article-title>Binding of complement factor H to endothelial cells is mediated by the carboxy-terminal glycosaminoglycan binding site</article-title>
<source>Am. J. Pathol</source>
<year>2005</year>
<volume>167</volume>
<fpage>1173</fpage>
<lpage>81</lpage>
<pub-id pub-id-type="pmid">16192651</pub-id></element-citation>
      </ref>
      <ref id="R20">
        <label>20</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Blackmore</surname><given-names>TK</given-names></name><etal/></person-group>
<article-title>Identification of the second heparin-binding domain in human complement factor H</article-title>
<source>J. Immunol</source>
<year>1998</year>
<volume>160</volume>
<fpage>3342</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="pmid">9531293</pub-id></element-citation>
      </ref>
      <ref id="R21">
        <label>21</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Blackmore</surname><given-names>TK</given-names></name><name><surname>Sadlon</surname><given-names>TA</given-names></name><name><surname>Ward</surname><given-names>HM</given-names></name><name><surname>Lublin</surname><given-names>DM</given-names></name><name><surname>Gordon</surname><given-names>DL</given-names></name></person-group>
<article-title>Identification of a heparin binding domain in the seventh short consensus repeat of complement factor H</article-title>
<source>J. Immunol</source>
<year>1996</year>
<volume>157</volume>
<fpage>5422</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="pmid">8955190</pub-id></element-citation>
      </ref>
      <ref id="R22">
        <label>22</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hageman</surname><given-names>GS</given-names></name><etal/></person-group>
<article-title>A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration</article-title>
<source>Proc. Natl. Acad. Sci. U. S. A</source>
<year>2005</year>
<volume>102</volume>
<fpage>7227</fpage>
<lpage>32</lpage>
<pub-id pub-id-type="pmid">15870199</pub-id></element-citation>
      </ref>
      <ref id="R23">
        <label>23</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Klein</surname><given-names>RJ</given-names></name><etal/></person-group>
<article-title>Complement factor H polymorphism in age-related macular degeneration</article-title>
<source>Science</source>
<year>2005</year>
<volume>308</volume>
<fpage>385</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="pmid">15761122</pub-id></element-citation>
      </ref>
      <ref id="R24">
        <label>24</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kuehn</surname><given-names>BM</given-names></name></person-group>
<article-title>Gene discovery provides clues to cause of age-related macular degeneration</article-title>
<source>Jama</source>
<year>2005</year>
<volume>293</volume>
<fpage>1841</fpage>
<lpage>5</lpage>
<pub-id pub-id-type="pmid">15840844</pub-id></element-citation>
      </ref>
      <ref id="R25">
        <label>25</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zareparsi</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Strong association of the Y402H variant in complement factor H at 1q32 with susceptibility to age-related macular degeneration</article-title>
<source>Am. J. Hum. Genet</source>
<year>2005</year>
<volume>77</volume>
<fpage>149</fpage>
<lpage>53</lpage>
<pub-id pub-id-type="pmid">15895326</pub-id></element-citation>
      </ref>
      <ref id="R26">
        <label>26</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wiesmann</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>Structure of C3b in complex with CRIg gives insights into regulation of complement activation</article-title>
<source>Nature</source>
<year>2006</year>
<volume>444</volume>
<fpage>217</fpage>
<lpage>20</lpage>
<pub-id pub-id-type="pmid">17051150</pub-id></element-citation>
      </ref>
      <ref id="R27">
        <label>27</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lian</surname><given-names>LY</given-names></name><name><surname>Barsukov</surname><given-names>IL</given-names></name><name><surname>Sutcliffe</surname><given-names>MJ</given-names></name><name><surname>Sze</surname><given-names>KH</given-names></name><name><surname>Roberts</surname><given-names>GC</given-names></name></person-group>
<article-title>Protein-ligand interactions: exchange processes and determination of ligand conformation and protein-ligand contacts</article-title>
<source>Methods Enzymol</source>
<year>1994</year>
<volume>239</volume>
<fpage>657</fpage>
<lpage>700</lpage>
<pub-id pub-id-type="pmid">7830601</pub-id></element-citation>
      </ref>
      <ref id="R28">
        <label>28</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Matsuo</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>Identification by NMR spectroscopy of residues at contact surfaces in large, slowly exchanging macromolecular complexes</article-title>
<source>J. Am. Chem. Soc</source>
<year>1999</year>
<volume>121</volume>
<fpage>9903</fpage>
<lpage>9904</lpage>
</element-citation>
      </ref>
      <ref id="R29">
        <label>29</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Daughdrill</surname><given-names>GW</given-names></name><etal/></person-group>
<article-title>Chemical shift changes provide evidence for overlapping single-stranded DNA- and XPA-binding sites on the 70 kDa subunit of human replication protein A</article-title>
<source>Nucleic Acids Res</source>
<year>2003</year>
<volume>31</volume>
<fpage>4176</fpage>
<lpage>4183</lpage>
<pub-id pub-id-type="pmid">12853635</pub-id></element-citation>
      </ref>
      <ref id="R30">
        <label>30</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>McAlister</surname><given-names>MSB</given-names></name><etal/></person-group>
<article-title>NMR analysis of interacting soluble forms of the cell-cell recognition molecules CD2 and CD48</article-title>
<source>Biochemistry</source>
<year>1996</year>
<volume>35</volume>
<fpage>5982</fpage>
<lpage>5991</lpage>
<pub-id pub-id-type="pmid">8634239</pub-id></element-citation>
      </ref>
      <ref id="R31">
        <label>31</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ferreira</surname><given-names>VP</given-names></name><etal/></person-group>
<article-title>The Binding of Factor H to a Complex of Physiological Polyanions and C3b on Cells Is Impaired in Atypical Hemolytic Uremic Syndrome</article-title>
<source>J. Immunol</source>
<year>2009</year>
<volume>182</volume>
<fpage>7009</fpage>
<lpage>7018</lpage>
<pub-id pub-id-type="pmid">19454698</pub-id></element-citation>
      </ref>
      <ref id="R32">
        <label>32</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lehtinen</surname><given-names>MJ</given-names></name><name><surname>Rops</surname><given-names>AL</given-names></name><name><surname>Isenman</surname><given-names>DE</given-names></name><name><surname>van der Vlag</surname><given-names>J</given-names></name><name><surname>Jokiranta</surname><given-names>TS</given-names></name></person-group>
<article-title>Mutations of factor H impair regulation of surface-bound C3b by three mechanisms in atypical hemolytic uremic syndrome</article-title>
<source>J. Biol. Chem</source>
<year>2009</year>
<volume>284</volume>
<fpage>15650</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="pmid">19351878</pub-id></element-citation>
      </ref>
      <ref id="R33">
        <label>33</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Morikis</surname><given-names>D</given-names></name><name><surname>Lambris</surname><given-names>JD</given-names></name></person-group>
<article-title>The electrostatic nature of C3d-complement receptor 2 association</article-title>
<source>J. Immunol</source>
<year>2004</year>
<volume>172</volume>
<fpage>7537</fpage>
<lpage>47</lpage>
<pub-id pub-id-type="pmid">15187133</pub-id></element-citation>
      </ref>
      <ref id="R34">
        <label>34</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ricklin</surname><given-names>D</given-names></name><name><surname>Ricklin-Lichtsteiner</surname><given-names>SK</given-names></name><name><surname>Markiewski</surname><given-names>MM</given-names></name><name><surname>Geisbrecht</surname><given-names>BV</given-names></name><name><surname>Lambris</surname><given-names>JD</given-names></name></person-group>
<article-title>Cutting edge: members of the Staphylococcus aureus extracellular fibrinogen-binding protein family inhibit the interaction of C3d with complement receptor 2</article-title>
<source>J. Immunol</source>
<year>2008</year>
<volume>181</volume>
<fpage>7463</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="pmid">19017934</pub-id></element-citation>
      </ref>
      <ref id="R35">
        <label>35</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bhattacharjee</surname><given-names>A</given-names></name><name><surname>Lehtinen</surname><given-names>MJ</given-names></name><name><surname>Kajander</surname><given-names>T</given-names></name><name><surname>Goldman</surname><given-names>A</given-names></name><name><surname>Jokiranta</surname><given-names>TS</given-names></name></person-group>
<article-title>Both domain 19 and domain 20 of factor H are involved in binding to complement C3b and C3d</article-title>
<source>Mol. Immunol</source>
<volume>47</volume>
<fpage>1686</fpage>
<lpage>91</lpage>
<pub-id pub-id-type="pmid">20378178</pub-id></element-citation>
      </ref>
      <ref id="R36">
        <label>36</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Prosser</surname><given-names>BE</given-names></name><etal/></person-group>
<article-title>Structural basis for complement factor H linked age-related macular degeneration</article-title>
<source>J. Exp. Med</source>
<year>2007</year>
<volume>204</volume>
<fpage>2277</fpage>
<lpage>83</lpage>
<pub-id pub-id-type="pmid">17893204</pub-id></element-citation>
      </ref>
      <ref id="R37">
        <label>37</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>CQ</given-names></name><etal/></person-group>
<article-title>The Central Portion of Factor H (Modules 10-15) Is Compact and Contains a Structurally Deviant CCP Module</article-title>
<source>J. Mol. Biol</source>
<year>2010</year>
<volume>395</volume>
<fpage>105</fpage>
<lpage>122</lpage>
<pub-id pub-id-type="pmid">19835885</pub-id></element-citation>
      </ref>
      <ref id="R38">
        <label>38</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Barlow</surname><given-names>PN</given-names></name><etal/></person-group>
<article-title>Solution structure of a pair of complement modules by nuclear magnetic resonance</article-title>
<source>J. Mol. Biol</source>
<year>1993</year>
<volume>232</volume>
<fpage>268</fpage>
<lpage>84</lpage>
<pub-id pub-id-type="pmid">8331663</pub-id></element-citation>
      </ref>
      <ref id="R39">
        <label>39</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Barlow</surname><given-names>PN</given-names></name><etal/></person-group>
<article-title>Solution structure of the fifth repeat of factor H: a second example of the complement control protein module</article-title>
<source>Biochemistry</source>
<year>1992</year>
<volume>31</volume>
<fpage>3626</fpage>
<lpage>34</lpage>
<pub-id pub-id-type="pmid">1533152</pub-id></element-citation>
      </ref>
      <ref id="R40">
        <label>40</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Szakonyi</surname><given-names>G</given-names></name><etal/></person-group>
<article-title>Structure of complement receptor 2 in complex with its C3d ligand</article-title>
<source>Science</source>
<year>2001</year>
<volume>292</volume>
<fpage>1725</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="pmid">11387479</pub-id></element-citation>
      </ref>
      <ref id="R41">
        <label>41</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hammel</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>A structural basis for complement inhibition by Staphylococcus aureus</article-title>
<source>Nat. Immunol</source>
<year>2007</year>
<volume>8</volume>
<fpage>430</fpage>
<lpage>7</lpage>
<pub-id pub-id-type="pmid">17351618</pub-id></element-citation>
      </ref>
      <ref id="R42">
        <label>42</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chen</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>Allosteric inhibition of complement function by a staphylococcal immune evasion protein</article-title>
<source>Proc. Natl. Acad. Sci. U. S. A</source>
<year>2010</year>
<comment>In Press</comment>
</element-citation>
      </ref>
      <ref id="R43">
        <label>43</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jokiranta</surname><given-names>TS</given-names></name><etal/></person-group>
<article-title>Structure of complement factor H carboxyl-terminus reveals molecular basis of atypical haemolytic uremic syndrome</article-title>
<source>Embo J</source>
<year>2006</year>
<volume>25</volume>
<fpage>1784</fpage>
<lpage>94</lpage>
<pub-id pub-id-type="pmid">16601698</pub-id></element-citation>
      </ref>
      <ref id="R44">
        <label>44</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Saunders</surname><given-names>RE</given-names></name><etal/></person-group>
<article-title>The interactive Factor H-atypical hemolytic uremic syndrome mutation database and website: update and integration of membrane cofactor protein and Factor I mutations with structural models</article-title>
<source>Hum. Mutat</source>
<year>2007</year>
<volume>28</volume>
<fpage>222</fpage>
<lpage>34</lpage>
<pub-id pub-id-type="pmid">17089378</pub-id></element-citation>
      </ref>
      <ref id="R45">
        <label>45</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Miller</surname><given-names>EC</given-names></name><name><surname>Roumenina</surname><given-names>L</given-names></name><name><surname>Fremeaux-Bacchi</surname><given-names>V</given-names></name><name><surname>Atkinson</surname><given-names>JP</given-names></name></person-group>
<article-title>Functional characterization of mutations in complement C3 that predispose to aHUS</article-title>
<source>Mol. Immunol</source>
<year>2010</year>
<volume>47</volume>
<fpage>2291</fpage>
</element-citation>
      </ref>
      <ref id="R46">
        <label>46</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fremeaux-Bacchi</surname><given-names>V</given-names></name><etal/></person-group>
<article-title>Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome</article-title>
<source>Blood</source>
<year>2008</year>
<volume>112</volume>
<fpage>4948</fpage>
<lpage>52</lpage>
<pub-id pub-id-type="pmid">18796626</pub-id></element-citation>
      </ref>
      <ref id="R47">
        <label>47</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Aslam</surname><given-names>M</given-names></name><name><surname>Perkins</surname><given-names>SJ</given-names></name></person-group>
<article-title>Folded-back solution structure of monomeric factor H of human complement by synchrotron X-ray and neutron scattering, analytical ultracentrifugation and constrained molecular modelling</article-title>
<source>J. Mol. Biol</source>
<year>2001</year>
<volume>309</volume>
<fpage>1117</fpage>
<lpage>38</lpage>
<pub-id pub-id-type="pmid">11399083</pub-id></element-citation>
      </ref>
      <ref id="R48">
        <label>48</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fernando</surname><given-names>AN</given-names></name><etal/></person-group>
<article-title>Associative and structural properties of the region of complement factor H encompassing the Tyr402His disease-related polymorphism and its interactions with heparin</article-title>
<source>J. Mol. Biol</source>
<year>2007</year>
<volume>368</volume>
<fpage>564</fpage>
<lpage>81</lpage>
<pub-id pub-id-type="pmid">17362990</pub-id></element-citation>
      </ref>
      <ref id="R49">
        <label>49</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Oppermann</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>The C-terminus of complement regulator Factor H mediates target recognition: evidence for a compact conformation of the native protein</article-title>
<source>Clin. Exp. Immunol</source>
<year>2006</year>
<volume>144</volume>
<fpage>342</fpage>
<lpage>52</lpage>
<pub-id pub-id-type="pmid">16634809</pub-id></element-citation>
      </ref>
      <ref id="R50">
        <label>50</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Okemefuna</surname><given-names>AI</given-names></name><etal/></person-group>
<article-title>The regulatory SCR-1/5 and cell surface-binding SCR-16/20 fragments of factor H reveal partially folded-back solution structures and different self-associative properties</article-title>
<source>J. Mol. Biol</source>
<year>2008</year>
<volume>375</volume>
<fpage>80</fpage>
<lpage>101</lpage>
<pub-id pub-id-type="pmid">18005991</pub-id></element-citation>
      </ref>
      <ref id="R51">
        <label>51</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Baker</surname><given-names>NA</given-names></name><name><surname>Sept</surname><given-names>D</given-names></name><name><surname>Joseph</surname><given-names>S</given-names></name><name><surname>Holst</surname><given-names>MJ</given-names></name><name><surname>McCammon</surname><given-names>JA</given-names></name></person-group>
<article-title>Electrostatics of nanosystems: application to microtubules and the ribosome</article-title>
<source>Proc. Natl. Acad. Sci. USA</source>
<year>2001</year>
<volume>98</volume>
<fpage>10037</fpage>
<lpage>41</lpage>
<pub-id pub-id-type="pmid">11517324</pub-id></element-citation>
      </ref>
      <ref id="R52">
        <label>52</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Young</surname><given-names>KA</given-names></name><name><surname>Chen</surname><given-names>XS</given-names></name><name><surname>Holers</surname><given-names>VM</given-names></name><name><surname>Hannan</surname><given-names>JP</given-names></name></person-group>
<article-title>Isolating the Epstein-Barr virus gp350/220 binding site on complement receptor type 2 (CR2/CD21)</article-title>
<source>J. Biol. Chem</source>
<year>2007</year>
<volume>282</volume>
<fpage>36614</fpage>
<lpage>25</lpage>
<pub-id pub-id-type="pmid">17925391</pub-id></element-citation>
      </ref>
      <ref id="R53">
        <label>53</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shaw</surname><given-names>CD</given-names></name><etal/></person-group>
<article-title>Delineation of the Complement Receptor Type 2-C3d complex by site-directed mutagenesis and molecular docking</article-title>
<source>J. Mol. Biol</source>
<year>2010</year>
<volume>404</volume>
<fpage>697</fpage>
<lpage>710</lpage>
<pub-id pub-id-type="pmid">20951140</pub-id></element-citation>
      </ref>
      <ref id="R54">
        <label>54</label>
        <element-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Leslie</surname><given-names>AGW</given-names></name></person-group>
<source>Recent changes to the MOSFLM package for processing film and image plate data</source>
<year>1992</year>
</element-citation>
      </ref>
      <ref id="R55">
        <label>55</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Evans</surname><given-names>P</given-names></name></person-group>
<article-title>Scaling and assessment of data quality</article-title>
<source>Acta. Crystallogr. D Biol. Crystallogr</source>
<year>2006</year>
<volume>62</volume>
<fpage>72</fpage>
<lpage>82</lpage>
<pub-id pub-id-type="pmid">16369096</pub-id></element-citation>
      </ref>
      <ref id="R56">
        <label>56</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>McCoy</surname><given-names>AJ</given-names></name><etal/></person-group>
<article-title>Phaser crystallographic software</article-title>
<source>J. Appl. Crystallogr</source>
<year>2007</year>
<volume>40</volume>
<fpage>658</fpage>
<lpage>674</lpage>
<pub-id pub-id-type="pmid">19461840</pub-id></element-citation>
      </ref>
      <ref id="R57">
        <label>57</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nagar</surname><given-names>B</given-names></name><name><surname>Jones</surname><given-names>RG</given-names></name><name><surname>Diefenbach</surname><given-names>RJ</given-names></name><name><surname>Isenman</surname><given-names>DE</given-names></name><name><surname>Rini</surname><given-names>JM</given-names></name></person-group>
<article-title>X-ray crystal structure of C3d: a C3 fragment and ligand for complement receptor 2</article-title>
<source>Science</source>
<year>1998</year>
<volume>280</volume>
<fpage>1277</fpage>
<lpage>81</lpage>
<pub-id pub-id-type="pmid">9596584</pub-id></element-citation>
      </ref>
      <ref id="R58">
        <label>58</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Murshudov</surname><given-names>GN</given-names></name><name><surname>Vagin</surname><given-names>AA</given-names></name><name><surname>Dodson</surname><given-names>EJ</given-names></name></person-group>
<article-title>Refinement of macromolecular structures by the maximum-likelihood method</article-title>
<source>Acta. Crystallogr. D Biol. Crystallogr</source>
<year>1997</year>
<volume>53</volume>
<fpage>240</fpage>
<lpage>255</lpage>
<pub-id pub-id-type="pmid">15299926</pub-id></element-citation>
      </ref>
      <ref id="R59">
        <label>59</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Emsley</surname><given-names>P</given-names></name><name><surname>Cowtan</surname><given-names>K</given-names></name></person-group>
<article-title>Coot: model-building tools for molecular graphics</article-title>
<source>Acta. Crystallogr. D Biol. Crystallogr</source>
<year>2004</year>
<volume>60</volume>
<fpage>2126</fpage>
<lpage>2132</lpage>
<pub-id pub-id-type="pmid">15572765</pub-id></element-citation>
      </ref>
      <ref id="R60">
        <label>60</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Davis</surname><given-names>IW</given-names></name><etal/></person-group>
<article-title>MolProbity: all-atom contacts and structure validation for proteins and nucleic acids</article-title>
<source>Nucleic Acids Res</source>
<year>2007</year>
<volume>35</volume>
<fpage>W375</fpage>
<lpage>W383</lpage>
<pub-id pub-id-type="pmid">17452350</pub-id></element-citation>
      </ref>
    </ref-list>
  </back>
  <floats-group>
    <fig id="F1" position="float">
      <label>Figure 1</label>
      <caption>
        <p>Introduction to C3b/C3d and complement factor H (FH). (<bold>a</bold>) The central event in complement activation is C3 cleavage to C3b by C3 convertase accompanied by attachment to surfaces mediated by the TED. In the presence of additional complement regulatory molecules C3b may be further degraded sequentially to iC3b, C3c, C3dg and C3d. C3d corresponds to the TED and remains surface-bound on the cell surface. (<bold>b</bold>) Complement FH has 20 CCPs and possesses multiple binding sites for different ligands. Disease-linked mutations have been reported throughout FH. Several recombinant fragments of FH were utilized in the current studies and are indicated by black brackets. aHUS - atypical hemolytic uremic syndrome; AMD - age-related macular degeneration.</p>
      </caption>
      <graphic xlink:href="ukmss-34061-f0001"/>
    </fig>
    <fig id="F2" position="float">
      <label>Figure 2</label>
      <caption>
        <p>Structure of the C3d:FH19â20 complex showing interacting domains and overall molecular architecture. All interacting amino acid residues are shown as sticks; H bonds are represented by dashed lines. The resolution of the electron density (2<italic>F</italic><sub>o</sub>-<italic>F</italic><sub>c</sub> map) map is 2.1 Ã and is contoured at 1Ï. (<bold>a</bold>) Modules 19 (residues 1108â1166) and 20 (residues 1167â1231) of FH are shown in green. Amino acids belonging to two interacting helices (<italic>Î±</italic>7 (cyan, residues 170â189) and <italic>Î±</italic>4 (purple, residues 106â118) of C3d (shown in grey) form the majority of interactions with FH. (<bold>b</bold>) Electrostatic surface representations of C3d and FH19â20 (calculated using the APBS plug-in for Pymol <xref ref-type="bibr" rid="R51">51</xref>) rotated 90Â° counter-clockwise and clockwise, respectively, from the orientations shown in (<bold>a</bold>). ((<bold>c</bold>) and (<bold>d</bold>)) Enlarged views of the C3d and FH19â20 interface.</p>
      </caption>
      <graphic xlink:href="ukmss-34061-f0002"/>
    </fig>
    <fig id="F3" position="float">
      <label>Figure 3</label>
      <caption>
        <p>Heteronuclear NMR spectroscopy used to map the C3d and dp8 binding sites on FH19â20. (<bold>a</bold>) The percentage broadening observed for unequivocally assigned backbone amides upon addition of C3d is indicated: Red bars signify &gt; 90% broadening; white bars indicate proline residues; and grey bars indicate residues whose assignments were missing or whose intensities were weak in free FH19â20. (<bold>b</bold>) Amides which experience a line-broadening &gt; 90% are schematically shown as red spheres on the structure of FH19â20 (2G7I). The sizes of the spheres have been adjusted to correlate with the degree of line-broadening that each amide cross-peak experiences: Larger spheres represent complete disappearance of the signal; smaller spheres represent signals broadened by &gt; 90% but which are still detectable. (<bold>c</bold>) Combined amide chemical shift changes upon addition of 8.5-fold excess of dp8. Blue bars indicate shift changes larger than the threshold (double the average shift change; corresponding residues mapped onto the structure of FH19â20 in <xref ref-type="fig" rid="F5">Fig. 5d</xref>), white and grey bar have the same meaning as in (<bold>a</bold>).</p>
      </caption>
      <graphic xlink:href="ukmss-34061-f0003"/>
    </fig>
    <fig id="F4" position="float">
      <label>Figure 4</label>
      <caption>
        <p>SPR studies of FH19â20 mutants binding to C3d. (<bold>a</bold>) Sensorgram showing the binding of wild-type FH19â20 to amine-coupled plasma-derived C3d. (<bold>b</bold>) <italic>K</italic><sub>D</sub> fitting of (<bold>a</bold>). (<bold>c</bold>) Sensorgram showing the very weak binding of FH19â20 D1119G to amine-coupled plasma-derived C3d. (<bold>d</bold>) Summary of affinity constants of FH fragments and mutants for recombinant C3d. (<bold>e</bold>) Surface representation of FH19â20 (2G7I) highlighting residues corresponding to mutations that change C3b binding <xref ref-type="bibr" rid="R31">31</xref>. (<bold>f</bold>) Surface representation of FH19â20 (2G7I) highlighting residues corresponding to mutations that change C3d binding. Ser1191 and Val1197 are buried residues. *Val1197 has been analyzed in the context of the double mutant S1191L V1197A. Leu1189 has been analyzed in the context of two distinct mutants: L1189R and L1189F. (<bold>g</bold>) Summary of the <italic>K</italic><sub>D</sub> values for complexes of mutants of FH19â20 and C3d mutants E117A (E1110A), D122A (D1115A) and E160A (E1153A), I164A (I1157A, with wild-type FH19â20 only) and E117A D122A (E1110A D1115A, with wild-type FH19â20 only). The <italic>K</italic><sub>D</sub> of the latter was ~30 mM. * indicates that the corresponding <italic>K</italic><sub>D</sub> value was extrapolated. Error bars (standard error of the mean) for the <italic>K</italic><sub>D</sub> measurements are indicated.</p>
      </caption>
      <graphic xlink:href="ukmss-34061-f0004"/>
    </fig>
    <fig id="F5" position="float">
      <label>Figure 5</label>
      <caption>
        <p>Potential model of FH engagement with surface bound C3b (<bold>a</bold>) Superposition (C3d on TED) of the C3d:FH19â20 complex and C3b:FH1â4 complex demonstrating the close proximity of FH modules 4 and 19. (<bold>b</bold>) The FH19â20:C3d structure (red and cyan) is shown superimposed (C3d on TED) onto the FH1â4:C3b structure (tan and gray). This FH model has been constructed by juxtaposition or superposition of the structures of FH5 (yellow) and FH6â8 (yellow-orange) and the SAXS-shape envelopes of FH8-15 (bright orange) and FH15-19 (orange). Structures are shown in cartoon representation; SAXS shape envelopes are shown in mesh. Note, the FH1â4 SAXS shape envelope (pale yellow) is superimposed onto the C3b:FH1â4 structure. (<bold>c</bold>) Close up view of the Î±4-Î±5 loop and the Î±6-Î±7 loop of C3d. Highlighted in orange are the residues Pro121 (Pro1092), Asp122 (Asp1093), Cys165 (Cys1136) and Gln168 (Gln1139) for which disease-associated mutations have been reported. (<bold>d</bold>) Close-up view of the FH19â20 interaction with TED highlighting residues also like to interact with self-surface markers. Amides experiencing considerable chemical shift perturbations upon exposure to dp8 are highlighted as blue spheres (corresponding to their nitrogen atoms). Residues Lys1188 and Arg1231, which exhibit the greatest perturbations upon addition of dp8, are indicated.</p>
      </caption>
      <graphic xlink:href="ukmss-34061-f0005"/>
    </fig>
    <fig id="F6" position="float">
      <label>Figure 6</label>
      <caption>
        <p>The location of mis-sense mutations associated with the development of (aHUS) (and Q1139A) mapped onto the structure of the C3d:FH19â20 complex. The side-chains of C3b mis-sense mutations are shown as blue sticks; side-chains of FH19â20 mis-sense mutations are shown as cyan sticks.</p>
      </caption>
      <graphic xlink:href="ukmss-34061-f0006"/>
    </fig>
    <table-wrap id="T1" position="float">
      <label>Table 1</label>
      <caption>
        <p>Data collection and refinement statistics</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th align="left" valign="top" rowspan="1" colspan="1"/>
            <th align="center" valign="top" rowspan="1" colspan="1">C3d:CFH19-20 crystal</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td colspan="2" align="left" valign="top" rowspan="1">
              <bold>Data collection</bold>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Space group</td>
            <td align="center" valign="top" rowspan="1" colspan="1">P1</td>
          </tr>
          <tr>
            <td colspan="2" align="left" valign="top" rowspan="1">Cell dimensions</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">â<italic>a, b, c</italic> (Ã)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">74.67, 82.99, 85.60</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">â<italic>Î±, Î², Î³</italic> (Â°)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">112.75, 110.13, 99.96</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Resolution (Ã)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">41.59-6.64 (2.21-2.10)</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">
              <italic>R</italic>
              <sub>merge</sub>
            </td>
            <td align="center" valign="top" rowspan="1" colspan="1">9.9 (46.5)</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">
              <italic>I / ÏI</italic>
            </td>
            <td align="center" valign="top" rowspan="1" colspan="1">14.9 (5.1)</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Completeness (%)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">95.9 (96.4)</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Redundancy</td>
            <td align="center" valign="top" rowspan="1" colspan="1">4.6 (4.7)</td>
          </tr>
          <tr>
            <td colspan="2" align="left" valign="top" rowspan="1">
              <bold>Refinement</bold>
            </td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">Resolution (Ã)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">41.59-2.10</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">No. reflections</td>
            <td align="center" valign="top" rowspan="1" colspan="1">93199</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1"><italic>R</italic><sub>work</sub> / <italic>R</italic><sub>free</sub></td>
            <td align="center" valign="top" rowspan="1" colspan="1">17.06/20.59</td>
          </tr>
          <tr>
            <td colspan="2" align="left" valign="top" rowspan="1">No. atoms</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">âProtein</td>
            <td align="center" valign="top" rowspan="1" colspan="1">9990</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">âLigand/ion</td>
            <td align="center" valign="top" rowspan="1" colspan="1">49</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">âWater</td>
            <td align="center" valign="top" rowspan="1" colspan="1">947</td>
          </tr>
          <tr>
            <td colspan="2" align="left" valign="top" rowspan="1">Average <italic>B</italic>-factors</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">âProtein</td>
            <td align="center" valign="top" rowspan="1" colspan="1">35.30</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">âLigand/ion</td>
            <td align="center" valign="top" rowspan="1" colspan="1">44.23</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">âWater</td>
            <td align="center" valign="top" rowspan="1" colspan="1">39.13</td>
          </tr>
          <tr>
            <td colspan="2" align="left" valign="top" rowspan="1">R.m.s. deviations</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">âBond lengths (Ã)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">0.007</td>
          </tr>
          <tr>
            <td align="left" valign="top" rowspan="1" colspan="1">âBond angles (Â°)</td>
            <td align="center" valign="top" rowspan="1" colspan="1">1.018</td>
          </tr>
        </tbody>
      </table>
      <table-wrap-foot>
        <p>Values in parentheses are for highest-resolution shell.</p>
      </table-wrap-foot>
    </table-wrap>
  </floats-group>
</article>

</metadata></record></GetRecord></OAI-PMH>